Olpress M 50 Tablet ER is a combination antihypertensive medication containing Olmesartan Medoxomil 20 mg and Metoprolol Succinate 50 mg. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, resulting in effective blood pressure reduction. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that decreases heart rate, cardiac output, and myocardial oxygen demand, contributing to improved cardiovascular function and blood pressure control. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing for enhanced patient compliance. Olpress M 50 is indicated for the management of essential hypertension, particularly in patients who require dual therapy for adequate blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure, under medical supervision. Common side effects include dizziness, fatigue, and gastrointestinal disturbances. Caution is advised in patients with bradycardia, heart block, or severe renal impairment. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Olpress M 50 should be used under the guidance of a healthcare professional to optimize therapeutic outcomes and minimize adverse effects.